Logo image of APM

APTORUM GROUP LTD-CLASS A (APM) Stock Fundamental Analysis

USA - NASDAQ:APM - KYG6096M1226 - Common Stock

2.2397 USD
+0.22 (+10.88%)
Last: 10/1/2025, 10:31:02 AM
Fundamental Rating

1

Overall APM gets a fundamental rating of 1 out of 10. We evaluated APM against 536 industry peers in the Biotechnology industry. Both the profitability and financial health of APM have multiple concerns. APM has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

APM had negative earnings in the past year.
APM had a negative operating cash flow in the past year.
APM had negative earnings in 4 of the past 5 years.
In the past 5 years APM always reported negative operating cash flow.
APM Yearly Net Income VS EBIT VS OCF VS FCFAPM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

With a decent Return On Assets value of -26.46%, APM is doing good in the industry, outperforming 71.46% of the companies in the same industry.
APM has a Return On Equity of -20.19%. This is amongst the best in the industry. APM outperforms 84.70% of its industry peers.
Industry RankSector Rank
ROA -26.46%
ROE -20.19%
ROIC N/A
ROA(3y)-29.03%
ROA(5y)-37.43%
ROE(3y)-31.31%
ROE(5y)-36.99%
ROIC(3y)N/A
ROIC(5y)N/A
APM Yearly ROA, ROE, ROICAPM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

APM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APM Yearly Profit, Operating, Gross MarginsAPM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

APM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APM has more shares outstanding
The number of shares outstanding for APM has been reduced compared to 5 years ago.
The debt/assets ratio for APM is higher compared to a year ago.
APM Yearly Shares OutstandingAPM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
APM Yearly Total Debt VS Total AssetsAPM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -9.02, we must say that APM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.02, APM is doing worse than 70.71% of the companies in the same industry.
APM has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of APM (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.02
ROIC/WACCN/A
WACC7.47%
APM Yearly LT Debt VS Equity VS FCFAPM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 0.22 indicates that APM may have some problems paying its short term obligations.
APM's Current ratio of 0.22 is on the low side compared to the rest of the industry. APM is outperformed by 94.96% of its industry peers.
A Quick Ratio of 0.22 indicates that APM may have some problems paying its short term obligations.
APM has a Quick ratio of 0.22. This is amonst the worse of the industry: APM underperforms 94.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.22
Quick Ratio 0.22
APM Yearly Current Assets VS Current LiabilitesAPM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

APM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.79%, which is quite good.
APM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)13.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to decrease by -16.88% on average over the next years. This is quite bad
EPS Next Y8528.57%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-78.44%
Revenue Next 2Y-60.2%
Revenue Next 3Y-38.21%
Revenue Next 5Y-16.88%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
APM Yearly Revenue VS EstimatesAPM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
APM Yearly EPS VS EstimatesAPM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

APM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
APM is valuated cheaply with a Price/Forward Earnings ratio of 0.04.
99.81% of the companies in the same industry are more expensive than APM, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.18. APM is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.04
APM Price Earnings VS Forward Price EarningsAPM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APM Per share dataAPM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

APM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTORUM GROUP LTD-CLASS A

NASDAQ:APM (10/1/2025, 10:31:02 AM)

2.2397

+0.22 (+10.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)12-18 2025-12-18
Inst Owners0.82%
Inst Owner ChangeN/A
Ins Owners2.57%
Ins Owner ChangeN/A
Market Cap15.99M
Analysts80
Price TargetN/A
Short Float %5.28%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.04
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)59.59
Fwd EY2660.62%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS2.96
TBVpS2.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.46%
ROE -20.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.03%
ROA(5y)-37.43%
ROE(3y)-31.31%
ROE(5y)-36.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.22
Quick Ratio 0.22
Altman-Z -9.02
F-Score2
WACC7.47%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.89%
EPS Next Y8528.57%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-78.44%
Revenue Next 2Y-60.2%
Revenue Next 3Y-38.21%
Revenue Next 5Y-16.88%
EBIT growth 1Y63.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-97.69%
EBIT Next 3Y-54.02%
EBIT Next 5Y-27.84%
FCF growth 1Y84.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.6%
OCF growth 3YN/A
OCF growth 5YN/A